Early-Phase Partial Mayo Score following Golimumab Treatment Is Associated with Endoscopic Improvement at 1 Year in Ulcerative Colitis: A post hoc Analysis of PURSUIT-J Randomized Controlled Trial

INTRODUCTION: Golimumab (GLM) is an anti-tumor necrosis factor-alpha antibody therapy for moderately to severely active ulcerative colitis (UC). Endoscopic improvement is considered one of UC treatment's main goals, and earlier prediction of future endoscopic improvement has clinical implicatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagano, Katsumasa, Imai, Yuya, Ukyo, Yoshifumi, Kobayashi, Taku, Yokoyama, Seiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091011/
https://www.ncbi.nlm.nih.gov/pubmed/37064537
http://dx.doi.org/10.1159/000526264

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091011/
https://www.ncbi.nlm.nih.gov/pubmed/37064537
http://dx.doi.org/10.1159/000526264

Ejemplares similares